Sonoma Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

3. Summary of Significant Accounting Policies (Details - Fair Value)

3. Summary of Significant Accounting Policies (Details - Fair Value) (USD $)	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2013
Liabilities:
Derivative liabilities - warrants	$ 11,000	$ 3,175,000	$ 0
Fair Value, Measurements, Recurring [Member]
Liabilities:
Derivative liabilities - warrants	11,000	3,175,000
Fair Value, Measurements, Recurring [Member] \| Level 1 [Member]
Liabilities:
Derivative liabilities - warrants	0	0
Fair Value, Measurements, Recurring [Member] \| Level 2 [Member]
Liabilities:
Derivative liabilities - warrants	0	0
Fair Value, Measurements, Recurring [Member] \| Level 3 [Member]
Liabilities:
Derivative liabilities - warrants	$ 11,000	$ 3,175,000

- Definition

Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.

+ References + Details